secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122810
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Q3 net loss $135.7M; cash $944.7M; FDA clears Phase 3 for nex-z polyneuropathy
--------------------------------------------------------------------------------

- Net loss $135.7M vs $122.2M YoY; cash $944.7M (down from $1.0B at Dec 31).
- FDA IND clearance for MAGNITUDE-2 Phase 3 trial of nex-z for ATTRv polyneuropathy; enrollment on track by year-end.
- MAGNITUDE Phase 3 (ATTR-CM) enrollment tracking ahead; HAELO Phase 3 (HAE) actively screening.
- Positive Phase 2 data for NTLA-2002: 8/11 patients attack-free after single 50mg dose; no serious AEs.
- On track to dose first patient in NTLA-3001 Phase 1/2 for AATD by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024122810/0000950170-24-122810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024122810/ntla-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer